Prostaglandin metabolism in the fetal and maternal vasculature

Federation Proceedings
|January 1, 1979
PubMed

The capacity of fetal and maternal blood vessels to synthesize the antithrombotic vasodilator agent prostacyclin (PGI2) suggests that this substance participates in the circulatory adjustments to pregnancy. We studied the capacity of fetal and maternal blood vessels to metabolize [1(-14)C]arachidonic acid; thin-layer chromatography was used to separate PGE2, PGF2alpha, and 6-keto-PGF1alpha (the stable hydrolysis product of PGI2), and these were then quantitated by scintillation counting. Fetal vascular tissues (aorta, ductus arteriosus, and pulmonary arteries) generated tenfold more PGI2 than PGE2. Prostacyclin accounted for more than 50% of the prostaglandins synthesized by fetal blood vessel measured by recovery of its hydrolysis product, 6-keto-PGF1alpha. In contrast, in the mature animals, the aorta and pulmonary artery generated less PGI2 than did fetal tissue, whereas the mesenteric arteries exhibited high biosynthetic capacity comparable to that of the fetal vasculature. Release of prostaglandins by the umbilical blood vessels and ductus arteriosus was also measured by mass fragmentography. The identity of 6-keto-PGF1alpha was confirmed by mass spectroscopy. The high and almost identical capacity of all fetal blood vessels, except the umbilical arteries and veins, to synthesize PIG2 could reflect an important role for this prostaglandin in the regulation of the fetal circulation.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Physiological Barriers01:25

Physiological Barriers

Physiological barriers are semi-permeable cellular structures restricting drug diffusion into intracellular compartments and tissues. There are six types of physiological barriers: blood endothelial, cell membrane, blood-brain, blood-cerebrospinal fluid (CSF), blood-placenta, and blood-testis barriers.
The blood endothelial barrier is the most porous of these. It allows all small ionized, un-ionized, and lipophilic molecules to pass through the endothelial lining into the interstitial space...
Development of Blood Vessels01:07

Development of Blood Vessels

The development of the vascular system in a fetus is a complex and intricate process that begins as early as 15 to 16 days post-conception. This process starts outside the embryo, specifically in the mesoderm of the yolk sac, chorion, and connecting stalk. Approximately two days later, the formation of blood vessels occurs within the embryo itself.
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
Fetal Circulation01:14

Fetal Circulation

Fetal circulation is a unique system that facilitates the exchange of gases, nutrients, and waste products between the developing fetus and the mother. This intricate process takes place through a special organ called the placenta.
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...